Silverarc Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Silverarc Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-146,657	Closed	-$6.6M	–	76
2024 Q3	$6.6M	Buy	+146,657	New	+$5.93M	1.48%	21
2023 Q3	–	Sell	-25,000	Closed	-$691K	–	97
2023 Q2	$691K	Sell	25,000 -80,486	-76%	-$2.01M	0.21%	65
2023 Q1	$2.43M	Buy	+105,486	New	+$1.77M	1%	39
2021 Q1	–	Sell	-20,910	Closed	-$422K	–	100
2020 Q4	$422K	Buy	+20,910	New	+$450K	0.25%	75

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Silverarc Capital Management's PTGX Position: Q4 2024 in Review

Silverarc Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 146,657 shares — an estimated $6.6M sold.

Silverarc Capital Management first reported a position in PTGX in Q4 2020 and held it in 4 quarters. The position peaked at $6.6M in Q3 2024. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

Silverarc Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
Silverarc Capital Management sold 146,657 Protagonist Therapeutics shares in Q4 2024, an estimated $6.6M.
Silverarc Capital Management first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 4 quarters.
Silverarc Capital Management's Protagonist Therapeutics position peaked at $6.6M in Q3 2024.
241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.